This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Her-2/neu T-cell vaccine, Her2/neu T-cell vaccine
Description: Corixa's HER-2/neu is an encapsulated Her-2/neu peptide p369-377 in poly(lactide-co-glycolide) microspheres used as a breast cancer vaccine. This immunotherapy is based upon a cancer antigen that was developed during a vaccine discovery collaboration with GSK.
In May 2005, GSK announced it would acquire Corixa.
Additional information available to subscribers only: